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Abstract: Recently, a computational approach combining a structure-activity relationship library 
containing pairs of halogenated ligands and their corresponding unsubstituted ligands (called XSAR) 
with QM-based molecular docking and binding free energy calculations was developed and used 
to search for amino acids frequently targeted by halogen bonding, also known as XB hot spots. 
However, the analysis of ligand-receptor complexes with halogen bonds obtained by molecular 
docking provides a limited ability to study the role and significance of halogen bonding in biological 
systems. Thus, a set of molecular dynamics simulations for the dopamine D4 receptor, recently 
crystallized with the antipsychotic drug nemonapride (5WIU), and the five XSAR sets were performed 
to verify the identified hot spots for halogen bonding, in other words, primary (V5x40), and secondary 
(S5x43, S5x461 and H6x55). The simulations confirmed the key role of halogen bonding with V5x40 
and H6x55 and supported S5x43 and S5x461. The results showed that steric restrictions and the 
topology of the molecular core have a crucial impact on the stabilization of the ligand-receptor 
complex by halogen bonding.
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1. Introduction
Halogen atoms are lipophilic substituents commonly used in the design of novel biologically 
active molecules to improve their pharmacokinetic profile via, for example, improvement of membrane 
permeability [1], blood-brain barrier penetration [2] (in the case of Central Nervous System (CNS) active 
compounds), and metabolic stability [3,4]. During recent decades, it has been widely described that 
covalently bound halogen atoms (Cl, Br, I) have the ability to form halogen bonds (XBs), acting as donors 
in a non-covalent directional interaction with a Lewis base as an acceptor [5,6]. This phenomenon 
is associated with the existence of a cr-hole— a region of depleted electron density, which partially 
exposes a positive nuclear charge [7,8]. The XB strength is comparable to weak or moderate hydrogen 
bonds and increases in the order Cl <  Br <  I. As fluorine atoms are more electronegative and less 
polarizable than other halogens, they do not form halogen bonds. There is clear evidence indicating 
that XBs play an essential role in supramolecular systems, liquid crystal engineering, nanomaterials, 
nanowire formation, and catalysis [9 ]. According to recent literature, this non-covalent interaction 
provides new perspectives for drug design, as it appears that the substitution of chemical scaffolds
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with halogen atoms may significantly improve biological activity [10,11]. Hence, it seems reasonable 
to deeply analyze the binding pocket of a particular protein target in terms of the presence of potential 
halogen bond acceptors, thus providing support for the design of novel ligands by indicating in which 
position(s) halogen atom(s) should be introduced.
Molecular dynamics (MD) simulations of complexes with halogen bonding have been the subject 
of only a few studies [12- 14], mainly because it is difficult to properly describe the anisotropy of the 
electron density of halogen atoms using the available force fields; instead, atoms are defined by the 
type of atom and their partial charge, and consequently, the possibility of the formation of both halogen 
bonds (u-holes) and/or hydrogen bonds (in perpendicular planes to the C -X  bonds, where X atoms 
have electronegative crowns) are not addressed. The first attempt to address the problem of the u-hole 
in calculations using force fields was based on the introduction of an off-center positive point charge, 
an extra site (massless dummy atom) located near the halogen atom [15]. This was successfully applied 
by Ibrahim et al. in AMBER [16], then Jorgensen et al. in OPLSA-AA [17], as well as by Hobza et al. 
who introduced the correction called explicit u-hole (ESH) implemented in the UCSF DOCK molecular 
docking suite [18]. Another approach, going beyond the partial charge approximation, uses electric 
multipole expansion (by the sum of multipoles) to describe the anisotropy of the electron density of the 
halogen atom. However, compared to the off-center positive partial charge approach, the contribution 
of multipole expansion in molecular dynamics software is still limited [15]. A completely different 
approach was proposed by Shing Ho et al., whose research group implemented a new potential energy 
function (ffBXB) to cover the anisotropy of the XB interaction in the AMBER force field [19].
The dopamine D4  receptor (D4 R) is a subtype of the D2 -like family belonging to the rhodopsin-like 
aminergic G protein-coupled receptors (GPCRs). The great attention to D4R started in 1991, when it 
turned out that clozapine (a well-known atypical antipsychotic agent: compound 1, Figure 1) has a 
much higher affinity for D4  than for the dopamine D2  receptor [20]. This discovery suggested refining 
the dopamine hypothesis of schizophrenia and considering D4 R involvement in the abovementioned 
pathophysiological process. It gave hope for the omission of D 2 R receptor activation, which 
was proposed to be responsible for extrapyramidal side effects and tardive dyskinesias [2 1 ,2 2 ]. 
Unfortunately, selective D4 R antagonists, compounds L-745,870 (2) [23] and sonepiprazole (3) [24], 
failed in clinical trials in 1 9 9 7  and 2 0 0 4 , respectively, showing no effects in schizophrenia patients. 
These results led to a significant decrease in attention focused on D4R as a therapeutic target for decades. 
The situation started to change over the last few years [25] due to the indication of novel, potential 
non-schizophrenia-like applications of D 4 R antagonists such as in cocaine use disorders [26] and 
L-DOPA-induced dyskinesias [27]. Moreover, the most recent studies have shown that D4 R antagonists 
selectively inhibit the growth of glioblastoma neural stem cells, thus suggesting a place for a new 
approach to fight with an aggressive and treatment-resistant type of cancer: glioblastoma multiforme 
(GBM) [28]. Finally, studies performed using an agonist, compound 4 (Figure 1), indicated that D4R 
activation may be a very promising approach to treat potential visual deficits [29]. Nevertheless, 
many questions remain, and it seems to be necessary to search for novel potent D4 R ligands. Fortunately, 
in the last year, the crystal structure of the dopamine D4  receptor was determined in complex with 
the known antipsychotic drug, nemonapride, compound 5 (Figure 1) [30], which allows for a better 
understanding of the protein-ligand interactions and enables more effective design of new ligands.
Figure 1. Structures of D4  receptor (D4 R) ligands: a well-known atypical antipsychotic clozapine 
(1) [20], selective antagonists L-745,870 (2) and sonepiprazole (3) [31] evaluated in clinical trials, the 
selective agonist PD 168,077 (4) [32], and the non-selective agonist nemonapride (5) [33].
Recently, we described a theoretical-experimental approach to define the amino acid hot spots 
of halogen bonding (i.e., amino acids frequently targeted by halogen bonding in L -R  complexes) in 
another aminergic GPCR class A member, the serotonin 5 -HT7  receptor [8]. The identification of amino 
acid hot spots in the binding pocket can significantly support the lead optimization process, directly 
indicating the position(s) where halogen substituent(s) should be introduced into non-halogenated 
analogues to improve affinity. To confirm that this paradigm may be applied for the design and/or 
optimization of ligands of any protein target, XSAR analysis was additionally performed for D 4 R, 
whose crystal structure has been recently deposited in the Protein Data Bank. The study led to 
the identification of frequently targeted amino acids by halogen bonding (formed with backbone 
carbonyl oxygen -c, or with the amino acid side chain -s), in other words, the primary (the GPCRdb 
generic numbering scheme) V5x40/V193 (c), and the secondary S5x43/S196 (c), S5x461/S200 (c, s), 
and H6x55/H414 (s). However, the computational workflow included molecular docking to a set of 
crystal structure conformations of the D 4  receptor tuned by an induced-fit docking approach. Since the 
ligand-protein complex is a dynamic system, the docking procedure used is not entirely appropriate 
to study the significance of particular interactions; for instance, because a given interaction forms 
and breaks over time. Hence, it was reasonable to perform molecular dynamic (MD) simulations to 
more rationally define the role of particular interactions in the L-R  complex and to verify whether the 
complex geometry remained stable during the whole simulation.
As the OPLS3 force field from Schrödinger offers parametrization for halogen bonds, we decided 
to verify the amino acid hot spots of halogen bonding previously identified for D4 R by molecular 
docking of the XSAR library [8]. For this purpose, several D4 R XSAR sets (Figure 2) representing 
different chemotypes, which were found to form halogen bonds with hot spots, were used to perform 
a set of 60 ns-long MD simulations. Trajectory analysis, with particular emphasis on the evolution of 
the geometry of potential halogen bonds in the studied L-R  complexes, were used to confirm the role 
of the XB hot spots and the importance of this interaction in the stabilization of the L -R  complex.
Figure 2. Selected XSAR sets of D4 R, which were used in the molecular dynamic (MD) simulations 
study (A- E). For each set, its chemotype, halogenated derivatives used, their activity towards the D4 
receptor, Xeffect factor (i.e., the fold of activity change after halogenation), and amino acid hot spots for 
halogen bonds (XB) that were identified in the previous study [8 ] on the basis of molecular docking 
are shown. The alignment of the most frequently observed molecular patterns among XSAR sets (F) 
showing the function of the given fragments with respect to the binding mode and the distance between 
the positive ionizable group (PI) and the center of the aromatic ring (AR).
2. Results and Discussion
2.1. The 5WIU: MD Simulation o f the D4 Receptor in Complex with Agonist Nemonapride
This study started with the analysis of the recently crystallized complex of D4 R with the agonist 
nemonapride (PDB code: 5WIU) [30] to verify the formation of halogen bonds in this complex and 
its stability during MD simulations. The initial geometry was retrieved from the native crystal 
structure, where the halogen bond with V5x40 was indicated (XB distance d(Cl—O) = 3.7 A, and a-hole 
angle =  163.2°). Comparison of the initial binding mode (grey, Figure 3A ) with the most populated 
geometry (cyan, Figure 3A ) obtained by clustering of the MD trajectory confirms the maintenance 
of both key interactions for D4 R: salt bridge with D3x32 and halogen bond with V5x40. To gain 
deeper insight into the impact of the halogen bond with V5x40, a multivariate plot showing the 
dependence of the XB distance Cl—O versus the a-hole angle C -C l—O for each trajectory frame was 
generated (Figure 3B). The plot area was divided into two regions, in other words, the green region, 
which represents a geometrically correct halogen bond (the primary XB), and the red region, where 
no halogen bond formation is observed. The remaining two regions, with adequate parameters of 
XB distance <  4.0 A, a-hole angles <  140°, XB distance >  4.0 A, and a-hole angles >  140°, indicate 
the formation of weak halogen bonds (secondary XB). As previously revealed, this type of XB is 
not irrelevant due to its frequent occurrence in biological systems [10]. To simplify the multivariate 
plot (too high data point density) of the XB geometry distribution during the simulation, points 
corresponding to the medians obtained for the trajectory divided into 6  ns-long intervals were 
introduced (Figure 3C). In this plot, the fluctuations of XB geometry between primary and secondary 
XB areas are clearly visible. Additionally, conformational changes of ligands were irrelevant (the RMSD 
value <  1 . 0  A during the whole simulation). Fluctuations of geometric parameters of halogen bond 
with V5x40 (XB geometry stays in primary XB area for 59% of the simulation time, average distance 
=  3.8 ± 0.4 A; a-hole =  145.0 ± 14.3°; Figure 3E) are significant, which means that XB is formed and 
broken dynamically, switching from a strong (primary XB area, Figure 3B,C) to a weak interaction 
(secondary XB area Figure 3B,C). Interestingly, this correlates very well with the low values of the 
crystal temperature factors (B-factor) for atoms involved in the XB. In summary, the halogen bond
with V5x40 is an important factor determining the binding mode of nemonapride with D4 R. Moreover, 
the significance of this interaction was recently indicated based on the ab initio FMO calculation in 
combination with PIEDA analysis [34]. The study showed that XB between V5x40 and nemonapride is 
mostly dispersion-dependent, which was additional evidence of the hydrophobic nature of XBs.
Figure 3. Illustration of the results obtained from the 60 ns-long MD simulation for nemonapride 
complexed with the D4  receptor (PDB ID: 5WIU). Comparison of the starting binding mode (crystal 
geometry; grey) with the most populated geometry (cyan) obtained from the clustering of the MD 
trajectory (A). The multivariate plot shows the dependence of the distance versus the a-hole angle 
for the halogen bond with V5x40 for each trajectory frame, divided into 6  ns-long interval ranges (B), 
and the reduced form of the plot presents the medians of the geometric parameters calculated for given 
time ranges of the trajectory (C). Change in the ligand RMSD during MD simulation (D ). The change in 
the distance and a-hole angle of the halogen bond with V5x40 during the MD simulation (E). Boxplots 
showing the distribution of the distance and the a-hole angle for each time interval of the MD trajectory 
(F). The labelling of amino acids was based on the GPCRdb generic numbering scheme.
2.2. The Use o f XSAR Sets to Explore the Validity ofX B  Hot Spots
In the next step, the XB hot spots for D4R were verified using five XSAR sets, which represent 
chemically diversified structural patterns (Figure 2A-E). Analysis of the XSAR library (Figure S1) 
showed that they may be grouped into two classes, differing in the distance between the two key 
pharmacophore features (Figure 2F, Table S1), in other words, the basic center (PI) and the aromatic 
ring (AR). The first, and most abundant class for which the PI-A R distance is longer (5.6 A) contains 
mainly an arylpiperazine fragment (rarely piperidine), and the second class (less numerous) for which 
the PI-A R distance is shorter (3.9 A; benzylpiperidine).
The plots illustrating the change in the distance and a-hole angle of XB with selected amino 
acid hot spots during the MD simulation performed for XSAR sets are available in the supplemental 
information (SI) (Figure S2).
2.2.1. MD Simulations for Sets Showing a Longer PI-A R Distance
As a first chemical pattern, two representative XSAR sets containing derivatives with halogenated 
arylpiperazine fragments were selected. Figure 4 presents the results obtained from the MD simulation 
for set51, in which the most active is the 2,3-diCl substituted analogue (122-fold increase in activity
compared with the unsubstituted analogue, while the 2-Cl derivative shows a 55-fold increase in 
activity). The initial complexes came from the induced-fit docking of compounds from set51 to the 
D4 R crystal structure [8 ]. The MD trajectory analysis showed stability of the complexes and only slight 
fluctuations in the geometry during the whole MD simulation (RMSD <  1.0 A). In complex with the 
2,3-diCl analogue (Figure 4A), the halogen bond with V5x40 is strongly involved in the binding mode. 
The XB geometry stays in the primary XB area for 71% of the simulation time, and the average distance 
and a-hole show slight deviations (3.8 ±  0.4 A; 163.7 ±  8 .2 °, respectively). Additionally, in this complex, 
the halogen bond with the H6x55 side-chain shows a noteworthy contribution to the binding mode, 
however, it should be qualified as a supporting interaction (stays only in the XB secondary area but 
near the XB primary border). This may be caused by a significantly stronger halogen bond with V5x40, 
which is crucial for positioning the arylpiperazine moiety in the binding pocket, thus making the XB 
with H6x55 a secondary interaction (XB geometry stays in primary XB area for 35% of the simulation 
time, average distance = 4.2 ±  0.5 A; a-hole = 153.0 ±  9.5°). To some extent, the proof of this concept is 
provided by the MD simulation for the 2-Cl analogue (Figure 4B), which shows that the formation of a 
halogen bond with the H6x55 side-chain is evident; the XB geometry occupies 89% of the simulation 
time in the XB primary area. The improvement of geometric parameters for the halogen bond and 
thus an increase in its interaction energy translates into a 55-fold increase in the activity of the 2-Cl 
analogue in relation to the unsubstituted compound. It should be noted, however, that the XB with the 
side chain is slightly more 'blurred' (average distance =  4.0 ±  0.4 A; a-hole =  151.5 ±  2 0 .8 °), which is 
probably caused by the mobility of this side chain.
Figure 4. Results of 60 ns-long MD simulation for set51 (A : 2,3-diCl, B: 2-Cl analogues) with the D4  
receptor. Comparison of the starting binding mode (induced fit docking; grey) with the most populated 
geometry (cyan) obtained from clustering of the MD trajectory. The medians' plot follows the changes 
in the distances and a-hole angles for the halogen bond with V5x40 and H6x55.
The next XSAR set31 (containing the halogenated arylpiperazine fragment) showed only slight 
differences between the geometries of the L-R  complexes obtained by the docking and MD procedures
(Figure 5). Analysis of the docking-based binding mode indicated that the 2,3-diCl derivative forms a 
halogen bond with the carbonyl oxygen of V5x40 and side chains of H6x55 and S5x43. MD simulations 
of this complex confirmed the stability of the binding mode (small dispersion of points in median 
plot, Figure 5) and the key role of XB with V5x40 (54% of the simulation time the geometry occupies 
the primary XB area, average distance =  3.9 ± 0.4 A; a-hole angle =  151.8 ± 11.6°). With a lesser 
but still significant impact, an XB with an S5x43 side chain (-OH group) is formed (stays only in 
the XB secondary area, but near the XB primary border and shows slight deviations from average 
values; average distance = 3.6 ± 0.5 A; a-hole angle = 133.8 ± 14.1°). On the other hand, the geometric 
parameters of the XB with the H6x55 side-chain show a 'blurring' tendency between unfavorable areas 
of XB formation and the secondary XB area (occupies the primary XB area only 12% of the simulation 
time with an average distance = 4.1 ± 0.5 A and a-hole angle = 130.6 ± 18.6°), which may be caused by 
the mobility of the H6x55 side chain. It is worth noting that in this case, even as the study describes the 
use of the same pattern as in XSAR set51, the additional XB with S5x43 is found to contribute to the 
binding mode. This may be a result of the different influences of diverse terminal fragments (Table S1: 
the halogenated fragment of arylpiperazines in the same position showed different influences on 
the Xeffect value), which induces different arylpiperazine positions in the binding pocket through 
interactions with the extracellular part of the receptor.
Xeffect = 24.3 (Kj = 11 nM) AAG = -4.31 kcal/mol Distance C l - X  [A]
Figure 5. Results of 60 ns-long MD simulation for set31 with the D4  receptor. Comparison of the 
starting binding mode (induced fit docking; grey) with the most populated geometry (cyan) obtained 
from clustering of the MD trajectory. The medians' plot follows the changes in the distances and a-hole 
angles for the halogen bond with the backbone of V5x40 and the side chains of S5x43 and H6x55.
2.2.2. MD Simulations for Sets Showing a Shorter PI-A R Distance
The chemical pattern that was analyzed next contained a halogenated benzylpiperidine fragment. 
There are just a few examples in the XSAR library (Table S1), however, it is interesting to use them in 
this study as a representation of a structure with a reduced distance between the AR-PI pharmacophore 
features for D4R ligands (compared to arylpiperazine-containing structures).
For this purpose, XSAR set27 was selected (Figure 2), for which changes in D4R affinity after 
halogenation are not relevant, and all positions of the benzyl group are substituted with chlorine. 
Additionally, our previous study [8 ] showed no interaction via halogen bonds for derivatives within 
this set, they were labelled as hydrophobic. Interestingly, all three MD simulations for the 2-Cl analogue 
indicated a significant destabilization of the starting complex, the ligand lost a key interaction (a salt 
bridge with D3x32 is broken, mainly as a result of inversion at the basic center), which refers to a 
tendency in activity changes (see Figure 2). MD simulations for the 3-Cl analogue (Figure 6 A) show that 
the secondary halogen bonds identified in the initial complex (i.e., with V5x40 and S5x44) are broken 
just after the first few nanoseconds of the simulation, and the complex switches to different binding 
mode, in which new, stable halogen bonds are formed with T3x37 (78% of simulation time in the 
primary XB area, average distance = 3.7 ± 0.5 A; a-hole angle = 165.1 ± 20.4°) and with S5x461 (mainly
occupies the secondary XB area, average distance =  3.6 ± 0.8 A; a-hole angle =  136.9 ± 16.2°). Finally, 
in the case of the 4-Cl derivative, the geometry of the initial complex changed rapidly, and the ligand 
accommodated a new binding mode in which no relevant halogen bond was observed (Figure 6 B). 
The performed MD simulations for this XSAR set indicated a lower preference of the benzylpiperidine 
scaffold to adopt a conformation in which the halogen atoms are exposed towards V5x40 and/or H6x55, 
and forcing deeper penetration into the binding pocket may be associated with the possibility of 
creating new XB contacts (in this case with T3x37).
Figure 6. Results of 60 ns-long MD simulation for set27 (A : 3-Cl, B: 4-Cl analogues) with the D4  receptor. 
Comparison of the starting binding mode (induced fit docking; grey) with the most populated geometry 
(cyan) obtained from clustering of the MD trajectory. The medians' plot follows the changes in the 
distances and a-hole angles for the halogen bond with backbone of V5x40, S5x44 and side chains of 
S5x461 and T3x37.
The XSAR set44, which contains a halogenated benzylmorpholine fragment, was used as 
another example with a decreased distance between the pharmacophore features of AR-PI (Figure 7). 
The previous study [8 ] indicated that the 3-Cl derivative does not form an optimal halogen bond 
(geometric parameters for the closest V5x40 are in an unfavorable area for an XB; Figure 7A). During the 
first 18 ns of MD simulation, the initial geometry changes and the 3-Cl-benzyl moiety penetrates deeper 
into the binding pocket. As a result, the secondary XBs with the S5x44 side chain (average distance 
3.4 ± 0.4 A; a-hole angle =  124.3 ± 17.9°) and F6x52 backbone (average distance =  4.4 ± 0.5 A; a-hole 
angle 159.4 ± 13.2°) are formed. For the 4-Cl analogue, the binding mode changed at the beginning of 
the MD simulation (Figure 7B); the 4-Cl-benzyl fragment penetrated deeper into the binding pocket 
forming the primary halogen bond with the S5x461 side chain (83% of the simulation time occupied 
the primary XB area; average distance =  3.4 ± 0.4 A; a-hole angle =  156.4 ± 16.8°), and a secondary 
halogen bond with the S5x43 backbone (average distance =  3.7 ± 0.4 A; a-hole angle =  132.6 ± 13.8°). 
Moreover, the 4-Cl analogue is almost 27-fold more active than the unsubstituted analogue, while the 
3-Cl derivative shows only a minor increase in affinity (1.3-fold). The results of the MD simulation 
indicate that the reason for the substitution-dependent influence on activity is probably concerned
with the formation of a halogen bond network with S5x461 and S5x43 by the 4-Cl analogue, thus 
causing an enhancement in L -R  complex stability. The 3,4-diCl derivative shows an identical activity 
increase as the 4-Cl analogue (Figure 2). Interestingly, substitution with a chlorine atom in position 
3 did not influence the activity in comparison to the monosubstituted 3-Cl derivative, for which a 
slight activity increase was observed. Analysis of the MD trajectories for the 3,4-diCl analogue was 
therefore partitioned into independent monitoring of the interaction of chlorine atoms in positions 
3 and 4 (medians' plot, Figure 7C). The results did not confirm the formation of stable halogen bonds. 
Nevertheless, the most populated MD simulation geometry shows halogen bonds with V5x40 and 
S5x43, which are not located in the primary XB area. Such a picture suggests that L-R  complex stability 
is caused by the rapid formation and breaking of various halogen bonds over time, which might be a 
result of the greater volume of the 3,4-diCl-benzyl fragment.
Figure 7. Results of 60 ns-long MD simulation for set44 (A : 3-Cl, B: 4-Cl, C: 3,4-diCl analogues) 
with the D4  receptor. Comparison of the starting binding mode (induced fit docking; grey) with the 
most populated geometry (cyan) obtained from clustering of the MD trajectory for 3-Cl (A), 4-Cl (B), 
and 3,4-diCl analogues (C).
2.2.3. MD Simulations for an Uncommon XSAR Set
Finally, an atypical chemical scaffold (set53), in which the distance between the pharmacophore 
features PI-A R is identical to those in set51 and set31 but does not belong to the arylpiperazine class, 
was used. Molecular docking indicates two XB hot spots, namely, S5x43 (with a carbonyl oxygen) 
and S5x461 (with a side chain). The MD simulations show that the initial complex geometry changed 
significantly, but key interactions for affinity to D4 R were maintained (Figure 8 ). The halogen bond 
with the S5x43 side chain (placed in the primary XB area) is broken during the first 6  ns and then stays 
in a non-XB area until the end of the MD simulation. Conversely, the halogen bond with the S5x461 
side chain occupies the secondary XB area (average distance = 3.3 ± 0.3 A; a-hole angle = 102.9 ± 6.9°), 
and the formation of a novel interaction with this amino acid is observed (29% of the simulation time 
stays in the primary XB area; average distance =  4.3 ± 0 . 6  A; a-hole angle 158.5 ± 1 0 .6 °).
Figure 8. Results of a 60 ns-long MD simulation for set53 with the D4  receptor. Comparison of the 
starting binding mode (induced fit docking; grey) with the most populated geometry (cyan) obtained 
from clustering of the MD trajectory. The medians' plot follows the changes of the distances and a-hole 
angles for the halogen bond with backbone of S5x43, S5x461 and side chain of S5x461.
3. Materials and Methods
3.1. Structure-Activity Relationship Datasets fo r  Halogenated Analogues
An algorithm to find all pairs containing halogenated and corresponding unsubstituted structures 
(called the XSAR library) was developed and used for the D4R target in our previous study [8]. 
To describe the influence of halogenation on the biological activity of the unsubstituted (parent) 
molecule, the Xeffect parameter was calculated as an activity (extracted from the ChEMBL database 
during generation of XSAR library) ratio of the parent compound to its halogenated derivative (an 
Xeffect between 0 and 1 denotes a decrease in the activity upon halogenation and an Xeffect greater 
than 1 means the fold of activity increased after halogen substitution).
3.2. Identification o f Halogen Bonding Hot Spots fo r  D4R
Privileged amino acids (i.e., hot spots) for halogen bonding for the D4 receptor were identified 
in our previous work using a procedure including the following steps: clustering the halogenated 
analogues representing each XSAR set, using the centroids of the clusters to tune the D4 receptor 
binding site by an induced-fit docking procedure, QPLD docking [35] of the XSAR library to D4R 
conformations, and determination of the number of halogen bonding interactions with the side chains 
and carbonyl oxygen atoms of amino acids in the docking poses.
In this study, the GPCRdb generic numbering scheme of amino acids was used [36]. This scheme 
is based on crystal structures and corrects for helix bulges and constrictions (identified by the 
structure-based sequence alignments of the recent GPCR crystal structure). For example, V5x40 denotes 
a valine in transmembrane helix 5, ten positions before the most conserved residue.
3.3. Molecular Dynamics Simulations
MD simulations (60 ns) were performed using Schrödinger (Schrödinger, New York, NY, USA) 
Desmond software [37,38]. The starting L -R  complexes selected by molecular docking analysis in our 
previous study [8] were immersed into a phosphatidylcholine (POPC, 300 K) membrane bilayer and 
positioned using the PPM web server (http://opm.phar.umich.edu/server.php, accessed 05-01-2019) [39]. 
Each system was solvated by water molecules described by the TIP4P potential, and the OPLS3 force 
field parameters were used for all atoms. Additionally, 0.15 M NaCl was added to mimic the ionic 
strength inside the cell. All simulations were performed on GPU processors, repeating each system 
three times. Only one trajectory was used to illustrate the results, showing the lowest variation of 
XB distance and angle values during the simulation. The output MD trajectories were hierarchically 
clustered into 10 clusters using trajectory analysis tools from the Maestro Schrödinger Suite. For further
analysis, the most populated complex was used. Based on obtained trajectories, the mean geometrical 
parameters of the selected halogen bonds (distance and angle) were calculated using the Simulation 
Event Analysis tool in Maestro Schrödinger Suite and further analyzed using in-house scripts written 
in R.
4. Conclusions
MD simulations for five XSAR sets were performed to extend our previous study of amino acid hot 
spots for halogen bonding of the recently crystalized dopamine D4  receptor. To select representative 
sets for simulation, the XSAR library was limited to those sets where halogenated ligands interacted 
with XB hot spots (i.e., V5x40, S5x43, S5x461, and H6x55). Structural analysis of the reduced XSAR 
library showed that two types of structural patterns can be distinguished: those containing a longer 
distance between key pharmacophore features PI-A R  (mainly arylpiperazines) and a shorter PI-A R 
distance (i.e., benzylpiperidines). The two examples of XSAR sets from each group and one set not 
directly classified in either of the two classes and native agonist nemonapride co-crystallized with D4 R 
were used to perform 60 ns-long MD simulations.
Trajectory analysis for XSAR sets containing the arylpiperazine fragment (set51 and set31) 
confirmed the key role of V5x40 as a hot spot for halogen bonds. In both sets, geometric parameters for 
XB with V5x40 were in the most energetically favorable areas (simultaneously the conditions of XB 
distance <  4.0 A and angle >  140° were fulfilled) for almost the whole simulation time and showed high 
stability (small standard deviations for the XB length and angle). It is worth noting that the halogenated 
derivatives in these sets (2,3-diCl in both sets and 2-Cl in set51) formed halogen bonds with H6x55 
(i.e., a chlorine in position 2  of the phenyl ring), which was classified as a supporting interaction (also 
having good geometrical parameters and a small standard deviation during simulation). Moreover, 
considering that the starting geometry of the ligands in both sets did not change significantly during 
the simulation, the changes in activity (Xeffect) of the halogenated derivatives in relation to the 
unsubstituted analogues showed a significant increase, and the above results of the MD simulation 
can confirm the hypothesis of the privileged role of halogen bonding with V5x40 and supporting 
(the secondary XB) interaction with H6x55. Additionally, the trajectory analysis for nemonapride 
confirmed the significant role of the XB bond with V5x40 (the XB geometry and its stability were 
slightly more blurred). Based on these findings, it can be concluded that the carbonyl oxygen of V5x40 
and/or nitrogen of H6x55 can be used as XB anchoring points for designing new D4  ligands containing 
arylpiperazine, piperidine, or an analogous fragment with a comparable PI-A R distance (e.g., set53).
Interestingly, the results of the M D simulations performed for sets representing a second class 
containing structures with shorter distance between PI-AR pharmacophore features (set44 and set 27) 
did not confirm the role of halogen bonding with V5x40 (set44), and the starting geometries in the first 
few ns of the simulation changed; they penetrated deeper into the binding pocket of the receptor. As a 
consequence, new halogen bonds were formed, mainly with the secondary hot spots S5x43 and S5x461 
indicated in the previous study and with T3x37 and F6x52, which had not been observed previously. 
It should be noted that in this case, the role of the halogen bond is less significant because the Xeffect 
values for these sets are lower than in the first class (where the XB with V5x40 was evident).
It should be mentioned that the privileged amino acids for halogen bonding in the D4  receptor 
validated in this study have already been identified as important for interactions with endogenous and 
synthetic ligands. For instance, Cummings et al. [40] performed a number of D 4  receptor mutations 
and found the key role of 5x43 and 5x461 serines in the formation of L-R  active complexes (mutation to 
alanine caused a drastic decrease in activity). In identical studies, but for the D2  receptor [41,42], the key 
role of the mentioned serines from helix 5 was also proven, and the multidimensional function of H6x55 
in ligand binding was additionally emphasized. The role of the XB with the carbonyl oxygen of S5x43 
in the D2  receptor was also indicated in MD simulations, which might trigger conformational changes 
in helix 5 that could consequently modify the overall stability of the ligand-receptor complex [13].
It should be stressed that S5x43, S5x461 and H6x55 are all conserved motifs in the structure of the 
D2-4 receptors.
The results of the M D simulations supported by the experimental data showed that steric 
restrictions of the receptor and the topology of the ligand's molecular core have a key impact on the 
stabilization of the L -R  complexes by halogen bonding. The level of enhancement in the activity of the 
halogenated derivative compared to its unsubstituted analogue depends on the stability of the halogen 
bond, the type of amino acid hot spot targeted, and the molecular pattern of the designed molecule. 
Finally, it seems that induced-fit docking may not be sufficient in binding mode analysis of XSAR sets, 
and thus MD simulations should be used next to study potential XB formation in L -R  complexes.
Supplementary Materials: The following are available online, Figure S1: The XSAR matrix for D4 R target, 
Figure S2: The dependency of the change in length and angle of the halogen bonds formed between the analogues 
from the XSAR library and the selected amino acid of the D4  receptor binding site, Table S1: Analysis of the XSAR 
library molecular scaffolds (chemotypes).
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